Parkinson's Disease Trial, Recruiting NCT04731246 Sponsor: Association de Recherche Bibliographique pour les Neurosciences Condition: Parkinson's Disease
Back to Parkinsons Disease

Parkinson's Disease Trial, Recruiting

NCT04731246
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You can be male or female
  • You have been clinically diagnosed with idiopathic Parkinson's Disease (Parkinson's that does not have a known external cause)
  • You have had a brain MRI scan done as part of your normal care within the last 12 months
  • You have had a specific brain scan (DaTSCAN or F-DOPA PET) done at any point before joining, which showed reduced dopamine activity in the brain
  • Your Parkinson's symptoms are in the mild-to-moderate range, based on a standard rating scale called Hoehn & Yahr (scores 1 to 3)
  • Your eye movement control is normal or only very slightly affected
  • You have no memory or thinking problems, or only very minor ones
  • You can read and speak French well enough to participate
  • You are covered by a health insurance plan
  • You are willing to sign a written consent form agreeing to take part
  • You have a caregiver who can support you during the trial

Who may not be able to join:

  • You have a significant mental health condition (mild to moderate anxiety or depression may still be acceptable — confirm with trial site)
  • You have a significant neurological condition in addition to Parkinson's
  • Your brain MRI shows notable problems with blood vessels in the brain, or any other brain condition including stroke (minor vascular changes may be acceptable — confirm with trial site)
  • You have severe memory or thinking difficulties
  • You show certain warning signs that suggest your condition may be a different brain disorder rather than Parkinson's, such as: balance or coordination problems, eye movement problems, symptoms only in the legs, perfectly symmetrical symptoms on both sides, early muscle stiffness or abnormal postures, signs of a specific type of dementia, speech or movement planning difficulties, early or frequent falls, early swallowing or speech problems, breathing difficulties, severe problems with automatic body functions (like blood pressure or bladder control), poor response to Parkinson's medication, or current use of certain medications that affect dopamine (confirm with trial site)
  • You have had a specific heart scan (MIBG myocardial scintigraphy) that came back as normal

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 7 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Philippe BARRES, MD, Centre Mémoire, Centre de Gérontologie Clinique RAINIER III, Princess Grace Hospital, Monaco.

Phone: +377 99995599

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Association de Recherche Bibliographique pour les Neurosciences
Registry
ClinicalTrials.gov
Start date
7 July 2021
Est. completion
1 January 2032

Where this trial is recruiting

Monaco

Primary endpoints

Change from Baseline of Oculomotor raw performance at 7 years - Latency in Horizontal saccades.; Change from Baseline of Oculomotor raw performance at 7 years - Main velocity in Horizontal saccades.; Change from Baseline of Oculomotor raw performance at 7 years - Gain in Horizontal saccades.; Change from Baseline of Oculomotor raw performance at 7 years - Latency in Vertical saccades.; Change from Baseline of Oculomotor raw performance at 7 years - Main velocity in Vertical saccades.; Change from Baseline of Oculomotor raw performance at 7 years - Gain in Vertical saccades.; Change from Baseli...

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 7 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov